These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21698839)

  • 1. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
    Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
    Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
    Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
    Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
    Cooper JE; Wiseman AC; Chan L
    Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
    Sberro-Soussan R; Zuberl J; Suberbielle-Boissel C; Legendre C
    Clin Transpl; 2010; ():409-14. PubMed ID: 21696059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting alloantibody production with bortezomib: does it make more sense?
    Lee I; Constantinescu S; Gillespie A; Rao S; Silva P; Birkenbach M; Leech S; Karachristos A; Daller JA; Sifontis NM
    Clin Transpl; 2010; ():397-403. PubMed ID: 21696057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
    Shapiro R; Lunz J; Zeevi A; Basu A; Mapara M; Randhawa P; Tan HP; Sharma V; Humar A
    Clin Transpl; 2010; ():405-7. PubMed ID: 21696058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
    Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
    Leyva S; Marino LA; Alberú J; Morales-Buenrostro LE
    Clin Transpl; 2010; ():369-82. PubMed ID: 21698837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
    Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
    [No Abstract]   [Full Text] [Related]  

  • 13. Proteasome inhibition for antibody-mediated rejection.
    Everly JJ; Walsh RC; Alloway RR; Woodle ES
    Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
    Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
    Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.
    Marino-Vázquez LA; Leyva S; Alberú J; Morales-Buenrostro LE
    Clin Transpl; 2010; ():363-7. PubMed ID: 21696054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers.
    Everly MJ
    Clin Transpl; 2010; ():353-62. PubMed ID: 21696053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract]   [Full Text] [Related]  

  • 19. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.